GCG and type 2 diabetes mellitus: As shown in the MASTER study, postprandial plasma aGLP-1 levels after 24-week combination treatment with miglitol plus sitagliptin were elevated to 11–14 pmol/L [19], whereas plasma concentrations of a GLP-1 receptor agonist (GLP-1 mimetic) liraglutide after its subcutaneous administration were demonstrated to be markedly increased to 4000–6000 pmol/L in T2D patients [25].